Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Pyridoxal Phosphate Anhydrous. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX2 | Q9UBL9 | 3/20 | 0.97 |
| ▸ | ESR1 | P03372 | 1/20 | 0.97 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.97 |
| ▸ | ACP1 | P24666 | 1/20 | 0.97 |
| ▸ | PDE4A | P27815 | 1/20 | 0.97 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.97 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | HPGD | P15428 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | PNPO | Q9NVS9 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.60 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.58 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.58 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.44 |
| ▸ | YWHAG | P61981 | 1/20 | 0.44 |
| ▸ | YWHAZ | P63104 | 1/20 | 0.44 |
| ▸ | PDXK | O00764 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyridoxal Phosphate Anhydrous SCHEMBL23158 | 0.99 | P2RX2 (1.00) | P2RX2ESR1PTGS1ACP1PDE4A | |
| Pyridoxal Phosphate Anhydrous SCHEMBL29362986 | 0.99 | P2RX2 (1.00) | P2RX2ESR1PTGS1ACP1PDE4A | |
| Pyridoxal Phosphate Anhydrous SCHEMBL827100 | 0.97 | P2RX2 (0.97) | P2RX2ESR1PTGS1ACP1PDE4A | |
| Pyridoxal Phosphate Anhydrous SCHEMBL20335524 | 0.97 | P2RX2 (0.97) | P2RX2ESR1PTGS1ACP1PDE4A | |
| Pyridoxal Phosphate Anhydrous SCHEMBL29392551 | 0.97 | P2RX2 (0.97) | P2RX2ESR1PTGS1ACP1PDE4A | |
| Pyridoxal Phosphate Anhydrous SCHEMBL2746592 | 0.97 | P2RX2 (0.97) | P2RX2ESR1PTGS1ACP1PDE4A | |
| Pyridoxal Phosphate Anhydrous SCHEMBL20335516 | 0.97 | P2RX2 (0.97) | P2RX2ESR1PTGS1ACP1PDE4A | |
| Pyridoxal Phosphate Anhydrous SCHEMBL28200961 | 0.93 | ESR1 (0.90) | P2RX2ESR1PTGS1ACP1PDE4A | |
| Pyridoxal Phosphate Anhydrous SCHEMBL10534222 | 0.92 | P2RX2 (0.88) | P2RX2ESR1PTGS1ACP1PDE4A | |
| Pyridoxal Phosphate Anhydrous SCHEMBL29424718 | 0.92 | P2RX2 (0.88) | P2RX2ESR1PTGS1ACP1PDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080214504-A1 | Vitamin B6 Related Compounds and Methods for Recovery From Trauma | MEDICURE INTERNATIONAL INC. (BB) | 2008-09-04 | — | — | US | claimed |
| US-5462858-A | Spreading layer containing transaminase substrate, reagent layer containing pyruvate oxidase, cofactors, chromogen, hardened gelatin layer and subbing layer separating reagent layer from spreading layer, support | EASTMAN KODAK COMPANY (US) | 1995-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214504-A1 | Vitamin B6 Related Compounds and Methods for Recovery From Trauma | PLPBP, PNPO, SERPINB6 | P2RX2 1070/4885ESR1 4824/4885PTGS1 292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.